Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Phase 1

Recruiting

Conditions: Advanced Renal Cell Carcinoma
Advanced Mesothelioma
Advanced Osteosarcoma

Interventions: Drug: CAR.70/IL15-transduced CB-derived NK cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2023-01-30

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT05703854

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Biological: MSC-IFNα
Drug: Nab paclitaxel
Drug: Cyclophosphamide
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2023-01-26

Last Posted Date: 2023-04-28

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 40

Registration Number: NCT05699811

Locations: 🇨🇳
Department of Biotherapeutic, Chinese PLA General Hospital, Beijing, China

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Biological: Pan-T booster co-expressing MSLN CAR T cell
Drug: Albumin-bound paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-01-23

Last Posted Date: 2024-05-10

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 15

Registration Number: NCT05693844

Locations: 🇨🇳
Kaichao Feng, Beijing, Beijing, China

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: PRGN-3007

First Posted Date: 2023-01-23

Last Posted Date: 2024-12-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT05694364

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions: Biological: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2023-01-12

Last Posted Date: 2024-12-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05681780

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2023-01-12

Last Posted Date: 2023-01-12

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 26

Registration Number: NCT05681728

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Phase 1

Recruiting

Conditions: HER2 Positive Advanced Solid Tumors

Interventions: Biological: HypoSti.CAR-HER2 T cells
Drug: Albumin-bound paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-01-12

Last Posted Date: 2023-12-12

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT05681650

Locations: 🇨🇳
Kaichao Feng, Beijing, Beijing, China

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Phase 3

Conditions: Peripheral T-cell Lymphoma Targeted Therapy

Interventions: Drug: Azacitidine
Drug: Cyclophosphamide
Drug: Chidamide
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 200

Registration Number: NCT05678933

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: AB-201
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-01-10

Last Posted Date: 2023-05-06

Lead Sponsor: Artiva Biotherapeutics, Inc.

Target Recruit Count: 133

Registration Number: NCT05678205

Locations: 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

First Posted Date: 2023-01-09

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1875

Registration Number: NCT05675410

Locations: 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 307 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy